News & Updates

Belimumab benefit sustained regardless of lupus nephritis status

15 Nov 2021 by

The recombinant human IgG-1λ monoclonal antibody belimumab improved renal outcomes in patients with relapsed and newly diagnosed* active lupus nephritis (LN), according to subgroup analysis results of the BLISS-LN** trial presented at ASN 2021.

Belimumab benefit sustained regardless of lupus nephritis status

15 Nov 2021

Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain

13 Nov 2021

About a third of patients who present to an emergency department with recent-onset low back pain fail to recover within 12 months, with factors such as higher pain levels and more pain sites, among others, being prognostic of complete nonrecovery within 6 months, according to a study.

Greater pain intensity, more pain sites predict nonrecovery from recent-onset low back pain

13 Nov 2021

Standard rituximab dose appears inadequate to maintain B cell depletion in AAV

07 Nov 2021

Rituximab maintenance dosing of 500 mg every 6 months may not be enough to maintain B cell depletion in the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), suggests a recent study.

Standard rituximab dose appears inadequate to maintain B cell depletion in AAV

07 Nov 2021

Denosumab inhibits joint destruction up to 3 years

06 Nov 2021

Treatment with denosumab prevents the progression of joint destruction up to 36 months, results of a Japan study have shown. Higher dosing frequency at an earlier treatment stage may help optimize treatment, based on effects on bone erosion score (BES) progression.

Denosumab inhibits joint destruction up to 3 years

06 Nov 2021

Erectile dysfunction in RA tied to lower risk of heart failure, myocardial infarction

05 Nov 2021 by

The incidence of erectile dysfunction (ED) is not statistically higher in patients with rheumatoid arthritis (RA), a study has found. ED also does not increase the overall rate of cardiovascular events in RA, but it contributes to an increased risk of peripheral arterial disease (PAD) and a decreased risk of myocardial infarction (MI), heart failure (HF), and death.

Erectile dysfunction in RA tied to lower risk of heart failure, myocardial infarction

05 Nov 2021

Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?

02 Nov 2021 by

In individuals receiving disease-modifying antirheumatic drugs* (DMARDs) for inflammatory rheumatic diseases** (IRD), humoral response remained satisfactory following administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2, a study suggests.

Do mRNA COVID-19 vaccines influence treatment for rheumatic diseases?

02 Nov 2021

ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis

28 Oct 2021 by

Interleukin-17 inhibition with the biologic disease-modifying antirheumatic drug (DMARD) secukinumab appears to produce a substantial reduction in synovitis in psoriatic arthritis, in addition to improvements in the signs and symptoms of the disease, according to the results of the phase III ULTIMATE.

ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis

28 Oct 2021

Which NSAID is most effective for osteoarthritis?

19 Oct 2021 by

The most effective nonsteroidal anti-inflammatory drugs (NSAIDs) for pain and function in patients with osteoarthritis (OA) are etoricoxib 60 mg/day and diclofenac 150 mg/day, suggests a study. However, these medications may not be suitable for those with comorbidities or for long-term use due to the slight increase in the risk of adverse events.